Skip to main content
Premium Trial:

Request an Annual Quote

ActivX Biosciences Wins $155K SBIR for Toxicity Research

NEW YORK, Aug. 1-The chemical proteomics firm ActivX Biosciences won a $155,000 Small Business Innovation Research grant for its toxicology research program, the company said today.


The grant, awarded by the National Cancer Institute, will fund six months of research. ActivX plans to investigate proteins as markers for toxicity. After identifying a set of proteins associated with toxic response, ActivX will create profiles that can be used to evaluate compounds for pharmaceutical development.


This award is the company's first SBIR grant. ActivX intends to apply for a Phase II SBIR grant to extend this research.


ActivX is a privately held firm in La Jolla, Calif.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.